An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks : A REFORM study. / Al-Khazali, Haidar M.; Ashina, Håkan; Christensen, Rune Häckert; Wiggers, Astrid; Rose, Kathrine; Iljazi, Afrim; Schytz, Henrik W.; Amin, Faisal Mohammad; Ashina, Messoud.
I: Cephalalgia, Bind 43, Nr. 10, 2023.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks
T2 - A REFORM study
AU - Al-Khazali, Haidar M.
AU - Ashina, Håkan
AU - Christensen, Rune Häckert
AU - Wiggers, Astrid
AU - Rose, Kathrine
AU - Iljazi, Afrim
AU - Schytz, Henrik W.
AU - Amin, Faisal Mohammad
AU - Ashina, Messoud
N1 - Publisher Copyright: © International Headache Society 2023.
PY - 2023
Y1 - 2023
N2 - Objective: To investigate whether clinical and sociodemographic factors are associated with calcitonin gene-related peptide (CGRP) induced migraine attacks. Methods: A total of 139 participants with migraine received a 20-minute intravenous infusion of CGRP (1.5 µg/min) on a single experiment day. The incidence of CGRP-induced migraine attacks was recorded using a headache diary during the 12-hour observational period post-infusion. Univariable and multivariable regression analyses were conducted to examine potential predictors' relationship with CGRP-induced migraine attacks. Results: CGRP-induced migraine attacks were reported in 110 (79%) of 139 participants. Univariable analysis revealed that participants with cutaneous allodynia had higher odds of developing CGRP-induced migraine attacks, compared with those without allodynia (OR, 2.97, 95% CI, 1.28 to 7.43). The subsequent multivariable analysis confirmed this association (OR, 3.26, 95% CI, 1.32 to 8.69) and also found that participants with migraine with aura had lower odds of developing CGRP-induced migraine attacks (OR, 0.32, 95% CI, 0.12 to 0.84). Conclusion: Our results suggest that cutaneous allodynia and aura play a role in CGRP-induced migraine attacks, while other clinical and sociodemographic factors do not seem to have any noticeable impact. This indicates that the CGRP provocation model is robust, as the CGRP hypersensitivity remained unaffected despite differences among a heterogeneous migraine population. Trial Registration: ClinicalTrials.gov Identifier: NCT04592952.
AB - Objective: To investigate whether clinical and sociodemographic factors are associated with calcitonin gene-related peptide (CGRP) induced migraine attacks. Methods: A total of 139 participants with migraine received a 20-minute intravenous infusion of CGRP (1.5 µg/min) on a single experiment day. The incidence of CGRP-induced migraine attacks was recorded using a headache diary during the 12-hour observational period post-infusion. Univariable and multivariable regression analyses were conducted to examine potential predictors' relationship with CGRP-induced migraine attacks. Results: CGRP-induced migraine attacks were reported in 110 (79%) of 139 participants. Univariable analysis revealed that participants with cutaneous allodynia had higher odds of developing CGRP-induced migraine attacks, compared with those without allodynia (OR, 2.97, 95% CI, 1.28 to 7.43). The subsequent multivariable analysis confirmed this association (OR, 3.26, 95% CI, 1.32 to 8.69) and also found that participants with migraine with aura had lower odds of developing CGRP-induced migraine attacks (OR, 0.32, 95% CI, 0.12 to 0.84). Conclusion: Our results suggest that cutaneous allodynia and aura play a role in CGRP-induced migraine attacks, while other clinical and sociodemographic factors do not seem to have any noticeable impact. This indicates that the CGRP provocation model is robust, as the CGRP hypersensitivity remained unaffected despite differences among a heterogeneous migraine population. Trial Registration: ClinicalTrials.gov Identifier: NCT04592952.
KW - CGRP hypersensitivity
KW - Headache disorders
KW - prediction
U2 - 10.1177/03331024231206375
DO - 10.1177/03331024231206375
M3 - Journal article
C2 - 37815254
AN - SCOPUS:85175587094
VL - 43
JO - Cephalalgia
JF - Cephalalgia
SN - 0800-1952
IS - 10
ER -
ID: 375727647